A Phase 3 interventional study of Bortezomib (VELCADE) and Bortezomib (VELCADE) in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 109 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-19.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing doxorubicin in Multiple Myeloma — none open to participants now, 2 under way, none of them phase 3. Doxorubicin · Multiple Myeloma.
Among the 45 studies testing doxorubicin in Multiple Myeloma, this one is the 2nd largest by enrollment of the 42 interventional ones that give a count, is one of 7 that started in 2004, is one of 6 in phase 3, and was the 10th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 45 studies testing doxorubicin in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →
Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 35 · Phase 3 6
First in 1995; this study’s year is marked. 7 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 646 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 40 across the 42 interventional studies. Of the 38 that completed or were terminated, 21 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 10th largest by enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2004, is one of 35 in phase 3, and was the 4th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
2 of the studies testing doxorubicin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03004287University of Arkansas2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | 2027-10 |
| NCT00869232University of ArkansasUARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 45 studies testing doxorubicin in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
This is a randomized (study drug assigned by chance), parallel-group, open-label (all involved people know the identity of the intervention), multicenter study in 18 countries. A total of 646 patients with multiple myeloma whose disease has progressed after an initial response to at least 1 line of prior therapy or was refractory to initial treatment will be enrolled. The primary endpoint is time to progression (the interval between the date of randomization and the date of disease progression); secondary endpoints are overall survival (the interval between the date of randomization and the patient's death from any cause), response rate (the proportion of patients in the evaluable population who achieved a complete or partial response), and safety. Other study endpoints include patient reported outcomes and exploratory pharmacogenics (to identify genetic markers of response). Patients are assessed for efficacy and safety every 3 weeks until disease progression is documented or for up to 42 weeks from the start of the first dose of study drug. Patients, who do not progress after the 42-week period, are assessed every 6 weeks until disease progression is documented. Efficacy evaluations includes: serum protein electrophoresis, 24-hour urine collection for protein electrophoresis, skeletal survey (plain films), bone marrow biopsy and aspirate, clinical or radiologic assessment of plasmacytomas, and serum calcium. Responses and progressions are assessed objectively by a computer algorithm based on the EBMT criteria. Safety evaluations include adverse event reports, changes in clinical laboratory findings, and tests for cardiac function (multiple gated acquisition scan/echocardiogram and electrocardiogram). Group A: VELCADE monotherapy: VELCADE 1.3 milligram per meter square (mg/m\^2) to be administered by i.v. bolus on Days 1, 4, 8, and 11 of each 21-day cycle. Group B: DOXIL/VELCADE combination: treated with VELCADE at the same dose and schedule as specified in Group A. DOXIL/CAELYX 30 mg/m\^2 by intravenous infusion given on Day 4 of every 21-day cycle following the administration of VELCADE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m\^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
Drug: Bortezomib (VELCADE)
Bortezomib (VELCADE) 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
Drug: Bortezomib (VELCADE) · Drug: Doxorubicin hydrochloride (DOXIL/CAELYX)
1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
Drug page: Doxorubicin
mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
Time to Progression (TTP)
Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of \>=25% from lowest level in Serum M-component or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]); Urine M component or (the absolute increase must be \>=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase \>10 mg/dL. Bone marrow plasma cell percentage \>=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.
Time frame: Up to 1 year and 4 months (From date of first participant randomization [20 December 2004] up to interim analysis cut-off date [28 April 2006])
Overall Survival
The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.
Time frame: Up to 9 years and 5 months (From date of first participant randomization [20 December 2004] to cut-off date for final survival analysis (16 May 2014)
Number of Participants With Serious Adverse Events (SAEs)
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Up to 1 year and 11 months (From date of first participant randomization [20 December 2004] to cut-off date for safety update (28 November 2006)
| Milestone | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) |
|---|---|---|
| Started | 322 | 324 |
| Completed | 0 | 0 |
| Not completed | 322 | 324 |
| Withdrew: Study closed by sponsor | 34 | 37 |
| Withdrew: Death | 257 | 253 |
| Withdrew: Lost to follow-up | 13 | 13 |
| Withdrew: Withdrawal by subject | 18 | 21 |
Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of \>=25% from lowest level in Serum M-component or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]); Urine M component or (the absolute increase must be \>=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase \>10 mg/dL. Bone marrow plasma cell percentage \>=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.
| Months | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) |
|---|---|---|
| Time to Progression (TTP) | 6.5 (5.6 to 7.1) | 9.3 (8.2 to 11.1) |
The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.
| months | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) |
|---|---|---|
| Overall Survival | 30.8 (25.2 to 36.5) | 33.0 (28.9 to 37.1) |
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 105 | 120 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Velcade (Bortezomib) Monotherapy | — | 105/318 (33%) | 299/318 (94%) |
| Doxil/Caelyx Plus Velcade (Bortezomib) | — | 120/318 (37.7%) | 313/318 (98.4%) |
| Event | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) |
|---|---|---|
| PneumoniaInfections and infestations | 20/318 | 16/318 |
| PyrexiaGeneral disorders | 8/318 | 15/318 |
| VomitingGastrointestinal disorders | 2/318 | 13/318 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/318 | 9/318 |
| DiarrhoeaGastrointestinal disorders | 6/318 | 7/318 |
| NauseaGastrointestinal disorders | 3/318 | 7/318 |
| DehydrationMetabolism and nutrition disorders | 6/318 | 6/318 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/318 | 2/318 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 2/318 | 5/318 |
| Herpes ZosterInfections and infestations | 3/318 | 5/318 |
| Event | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) |
|---|---|---|
| NauseaGastrointestinal disorders | 125/318 | 152/318 |
| DiarrhoeaGastrointestinal disorders | 122/318 | 142/318 |
| FatigueGeneral disorders | 88/318 | 115/318 |
| NeutropeniaBlood and lymphatic system disorders | 71/318 | 113/318 |
| ThrombocytopeniaBlood and lymphatic system disorders | 89/318 | 104/318 |
| ConstipationGastrointestinal disorders | 98/318 | 99/318 |
| VomitingGastrointestinal disorders | 67/318 | 93/318 |
| PyrexiaGeneral disorders | 67/318 | 91/318 |
| AnaemiaBlood and lymphatic system disorders | 67/318 | 80/318 |
| AstheniaGeneral disorders | 56/318 | 70/318 |
| Age, Continuous(years) | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) | Total |
|---|---|---|---|
| Mean | 61.5 ± 9.56 | 61.4 ± 9.61 | 61.4 ± 9.58 |
| Sex: Female, Male(Participants) | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) | Total |
|---|---|---|---|
| Female | 148 | 135 | 283 |
| Male | 174 | 189 | 363 |
| Region of Enrollment(participants) | Velcade (Bortezomib) Monotherapy | Doxil/Caelyx Plus Velcade (Bortezomib) | Total |
|---|---|---|---|
| ARGENTINA | 6 | 9 | 15 |
| AUSTRALIA | 31 | 31 | 62 |
| AUSTRIA | 12 | 6 | 18 |
| BELGIUM-LUXEMBURG | 6 | 14 | 20 |
| CANADA | 20 | 23 | 43 |
| CZECH REPUBLIC | 14 | 22 | 36 |
| FRANCE | 21 | 28 | 49 |
| GREAT BRITAIN | 8 | 7 | 15 |
| ISRAEL | 25 | 21 | 46 |
| ITALY | 17 | 11 | 28 |
| NETHERLANDS | 29 | 32 | 61 |
| POLAND | 35 | 17 | 52 |
| PORTUGAL | 6 | 14 | 20 |
| RUSSIA | 38 | 34 | 72 |
| SINGAPORE | 3 | 2 | 5 |
| SOUTH AFRICA | 13 | 15 | 28 |
| SPAIN | 20 | 15 | 35 |
| UNITED STATES OF AMERICA | 18 | 23 | 41 |
Showing the first 100 of 109 sites across 17 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2004, a primary completion of May 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxorubicin
Janssen Research & Development, LLC →